Texas Health Physicians Group

Fort Worth, Texas 76107

1 studies enrolling now · 15 studies all time

What they study most

Arthritis, Rheumatoid, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Diseases, Coronavirus Disease 2019 (COVID-19), Covid19, Diabetes Mellitus, Type 2, Dyslipidemia, Hypertension, Primary Prevention of Atherosclerotic Cardiovascular Disease, Type2 Diabetes

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) — Completed
• ACTIV-6: COVID-19 Study of Repurposed Medications — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) — Completed
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) — Completed
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) — Completed
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine) — Completed
• A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection — Stopped early
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone) — Completed
• ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) — Completed
• Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen — Completed
• Cardiovascular Inflammation Reduction Trial — Completed